Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06568952
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
Right Ventricular Function in Patients Taking Carfilzomib
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Right Ventricular Function of Patients With Multiple Myeloma Treated With Carfilzomib
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension This is well documented in the literature However there are no studies looking at right ventricular function in these patients both before and during treatment
Detailed Description:
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension This is well documented in the literature However there are no studies looking at right ventricular function in these patients both before and during treatment
Patients had a cardiac ultrasound scan prior to the introduction of carfilzomib and an ultrasound scan following the introduction of carfilzomib We will look at the evolution of right ventricular function parameters in these patients
Patients had a cardiac ultrasound scan prior to the introduction of carfilzomib and an ultrasound scan following the introduction of carfilzomib We will look at the evolution of right ventricular function parameters in these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None